Clinical trials: Lupus
Lupus Erythematosus, Systemic
Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
Exploratory clinical study of CNCT19 anti CD19 cell therapy in the treatment of refractory autoimmune diseases,To evaluate the safety and tolerability of CNCT19 in patients with refractory systemic lupus erythematosus (lupus…
- Trial name
- NCT06316791
- Testing
- single dose of CNCT19
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Juventas Cell Therapy Ltd.
Systemic Sclerosis, Systemic Lupus Erythematosus
Clinical Risk Assessment of Cognitive Function in Systemic Autoimmune Diseases
Objectives: Systemic autoimmune diseases are chronic diseases characterized by chronic inflammation, vasculopathy, and autoimmune phenomena. Several organ involvements are typical, including the central nervous system.
- Conditions
- Systemic Sclerosis, Systemic Lupus Erythematosus, Myopathies, Inflammatory, Rheumatoid Arthritis
- Trial name
- NCT06029335
- Where
- Hungary
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Pecs
Subacute Cutaneous Lupus Erythematosus
Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus
This study will assess the safety and efficacy of KRP203 in clinically active subacute cutaneous lupus erythematosus patients, who have demonstrated inadequate response to standard treatment, such as antimalarials.
- Trial name
- NCT01294774
- Testing
- KRP203 - 1.2mg
- Where
- 8 sites in Germany, Greece and 1 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus
Systemic lupus (SL) is a rare chronic autoimmune disease characterized by the production of autoantibodies directed against nuclear antigens, particularly native double-stranded deoxyribonucleic acid (DNA), and excessive…
- Trial name
- PENCIL (NCT06356740)
- Testing
- Blood sample, Treatment :Abacavir 600 mg/lamivudine 300 mg, Lupus Impact Tracker questionnaire
- Where
- 11 sites in France
- Volunteers
- 70 people
- Sponsor
- Hospices Civils de Lyon
Autoimmune Diseases
Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus
Several clinical studies have shown that rituximab is safe and effective for the induction of remission in moderate to severe systemic lupus erythematosus, and has been recommended by several guidelines for the induction of…
- Trial name
- NCT04127747
- Testing
- Standard dose of rituximab, Individualized dose of rituximab
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Lupus
Cardiac Imaging in Systemic Disorders: the ORACLES Registry
Autoimmune diseases affect a total of 5 to 10% of the population. These diseases are associated with an increased risk of developing cardiovascular pathologies.
- Trial name
- ORACLES (NCT07134166)
- Testing
- data collection
- Volunteers
- 1,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myasthenia Gravis, Systemic Lupus Erythematosus
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
The aim of this pilot study is to investigate the application of proteasome inhibitor Bortezomib (Velcade®, approved for therapy of multiple myeloma) in patients with therapy-refractory antibody-mediated autoimmune diseases.
- Conditions
- Myasthenia Gravis, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Trial name
- TAVAB (NCT02102594)
- Testing
- Bortezomib
- Where
- 2 sites in Germany
- Volunteers
- 11 people
- Sponsor
- Charite University, Berlin, Germany
Systemic Lupus Erythematosus
Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.
- Trial name
- NCT00624351
- Testing
- Epratuzumab
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 227 people
- Sponsor
- UCB Pharma
Systemic Lupus Erythematosus, Lupus Nephritis
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
This is an open-label investigator-initiated trial (IIT) to assess the safety, efficacy, and PK（pharmacokinetic）/PD（pharmacodynamics ） of UB-VV410 in adult subjects with clinically active treatment-refractory SLE.
- Trial name
- NCT07109986
- Testing
- UB-VV410
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Systemic Lupus
Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment
1. Estimation of serum ceramides level in SLE patients as anovel marker for renal impairment 2. Correlation serum ceramides level with histological classification of LN,C3,C4,ANA,ANTI DS DNA ,CRP ,ESR , eGFR , creatinine /protein…
- Trial name
- NCT04256577
- Testing
- serum ceramides level in blood
- Volunteers
- 90 people
- Sponsor
- Assiut University
Rheumatic Diseases, Gout
Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial
Non-adherence to evidence-based prescription medications results in preventable morbidity and mortality for middle-aged and older adults.
- Conditions
- Rheumatic Diseases, Gout, Adherence, Medication, Lupus Erythematosus, Systemic
- Trial name
- NCT04776161
- Testing
- Cue-Reward Intervention, Cue-Reward Intervention with possible intensification
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Brigham and Women's Hospital
Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus
- Trial name
- NCT06625671
- Testing
- DB-2304, Prednisone
- Where
- 7 sites in United States, Australia
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- DualityBio Inc.
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal…
- Conditions
- Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
- Trial name
- RESOLUTION (NCT07085104)
- Testing
- ALLO-329, Cyclophosphamide, Fludarabine
- Where
- 17 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Allogene Therapeutics
Systemic Lupus Erythematosus
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Systemic lupus erythematosus.
- Trial name
- NCT06920433
- Testing
- UCAR T-cell group
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Lupus Erythematosus, Systemic
Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus
OBJECTIVES: I. Evaluate the toxicity of cytarabine in patients with refractory systemic lupus erythematosus. II. Evaluate objective disease parameters, including serum complement levels, anti-DNA antibody titers, sedimentation…
- Trial name
- NCT00004643
- Testing
- cytarabine
- Volunteers
- 10 people
- Sponsor
- National Center for Research Resources (NCRR)
Lupus Nephritis
Identifying New Therapeutic Targets for Lupus Treatment
Lupus is an autoimmune disease affecting mainly young women (9/1). Lupus nephritis (LN) occurs in 30% of the cases of lupus and is associated with end stage renal disease (ESRD) in 17 to 25% of cases after 10 years.
- Trial name
- ELUDIAL (NCT03921398)
- Where
- France
- Volunteers
- 87 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lupus Nephritis
The Expression Profile of New Complement Components in Childhood Lupus Nephritis
The aim of this study was to evaluate whether C4d is a better biomarker and examine whether C4d plasma levels correlate with treatment response and C4d kidney deposition in systemic lupus erythematosus (SLE) with lupus nephritis…
- Trial name
- NCT05082363
- Testing
- C4d evaluation in lupus nephritis in serum and renal tissue
- Volunteers
- 30 people
- Sponsor
- Assiut University
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus
Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
In the Netherlands, the human Papillomavirus (HPV) vaccination will be added to the National Vaccination Program for girls to protect against the development of cervical cancer.
- Conditions
- Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Juvenile Dermatomyositis
- Trial name
- HPV-kind (NCT00815282)
- Testing
- Human papilloma virus vaccine (cervarix)
- Where
- 3 sites in Netherlands
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- N.M. Wulffraat
Relapsed/Refractory Autoimmune Diseases
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory autoimmune diseases.
- Trial name
- NCT06866080
- Testing
- LCAR-AIO T cells
- Where
- 4 sites in China
- Sponsor
- Nanjing Legend Biotech Co.
Systemic Lupus Erythematosus
Cardiology Prevention in Systemic Lupus Erythematosus (SLE)
We propose a feasibility study of aggressive CV risk factor management directed by preventive cardiology compared to usual care.
- Trial name
- NCT00610805
- Testing
- Preventive Cardiology, Usual Care
- Where
- 2 sites in United States
- Sponsor
- University of Pittsburgh